OSBORNE DAVID W 4
4 · Arcutis Biotherapeutics, Inc. · Filed Jul 12, 2022
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Sale
Common Stock
2022-07-08$25.41/sh−2,197$55,835→ 256,649 total
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 24,925 RSUs.
- [F4]Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022.